The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CRISPR Therapeutics AG shares valued at $826,564 were sold by Kulkarni Samarth on Dec 02 ’24. At $55.10 per share, Kulkarni Samarth sold 15,000 shares. The insider’s holdings dropped to 181,540 shares worth approximately $9.28 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Kulkarni Samarth sold 30,000 shares, netting a total of over 1,668,678 in proceeds. Following the sale of shares at $55.62 each, the insider now holds 196,540 shares.
Before that, KASINGER JAMES R. had sold 1,089 shares from its account. In a trade valued at $50,399, the General Counsel and Secretary traded CRISPR Therapeutics AG shares for $46.28 each. Upon closing the transaction, the insider’s holdings decreased to 1,089 shares, worth approximately $3.2 million.
As published in a research note from Needham on August 06, 2024, CRISPR Therapeutics AG [CRSP] has been retained to a Buy and the price target has been revised to $84. Analysts at Rodman & Renshaw started covering the stock with ‘”a Buy”‘ outlook in a report released in early August. Earlier on February 15, 2024, Wolfe Research initiated its rating. Their recommendation was “a Peer perform” for CRSP stock.
Analyzing CRSP Stock Performance
During the last five days, there has been a surge of approximately 3.71%. Over the course of the year, CRISPR Therapeutics AG shares have dropped approximately -18.31%. Shares of the company reached a 52-week high of $91.10 on 02/22/24 and a 52-week low of $43.42 on 09/06/24. A 50-day SMA is recorded $48.40, while a 200-day SMA reached $56.12. Nevertheless, trading volume fell to 1.46 million shares from 2.22 million shares the previous day.
Support And Resistance Levels for CRISPR Therapeutics AG (CRSP)
According to the 24-hour chart, there is a support level at 50.35, which, if violated, would cause prices to drop to 49.56. In the upper region, resistance lies at 52.12. The next price resistance is at 53.10. RSI (Relative Strength Index) is 53.86 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 3.29, which suggests the price will increase in the coming days. Percent R is at 43.64%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
